CD5 and B-cell chronic lymphocytic leukemia: The introduction of CD79b to the CD19/CD5/CD20 combination resulted in a 2-log increase in terms of sensitivity compared to conventional 4-color analysis including CD19, CD5 and Ig light chain clonality restriction, improving the prediction of outcome in CLL patients treated with alemtuzumab (10, 11).